Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are peptide hormones and growth factors. A major pathological feature of both Alzheimer’s dis-ease (AD) and Parkinson’s disease (PD) is the loss of synaptic transmission in the cortex in AD and the loss of dopaminergic synapses in the nigra-striatal dopaminergic projection. Several studies demonstrate that GLP-1 and GIP receptor agonists protect synapses and synaptic transmission from the toxic events that underlie AD and PD. In a range of AD animal models, treatment with GLP-1, GIP, or dual-GLP-1/GIP receptor agonists effectively protected cognition, synaptic trans-mission, long-term potentiation (LTP), and prevented the loss of synapses and neurons. In PD models, dopaminergic production resumed and synapses became functional again. Importantly, the GLP-1 receptor agonists exendin-4 and liraglutide have shown good protective effects in clinical trials in AD and PD patients. Studies show that growth factors and peptide drugs that can cross the blood–brain barrier (BBB) better are more potent than those that do not cross the BBB. We therefore developed dual-GLP-1/GIP receptor agonists that can cross the BBB at an enhanced rate and showed superior protective properties on synapses in animal models of AD and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“GLP-1 and GIP are peptide hormones and growth factors that play important physiological signaling roles to control cell metabolism and energy utilization (Baggio and Drucker, 2007; Doyle and Egan, 2007; Finan et al., 2016).”
BackgroundBlock of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123 · cited 4×
“An analysis of GLP-1R mRNA in patients with PD showed a 10-fold increase in the SN (Yun et al., 2018), indicating that GLP-1 levels in the brain are reduced,”
BackgroundInfluentialTansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 1×
“Synapse loss was reversed, and synaptic plasticity and memory formation in water maze tests was improved in mouse models of AD (Nagahara et al., 2009; Poon et al., 2009).”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 3×
“In this randomized, double-blind, and placebo-controlled phase II clinical study (NCT01971242) (Athauda et al., 2017), 60”
BackgroundGDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820 · cited 2×
“The growth factor signaling mechanism is reduced in the brains of AD and PD, and growth factors have neuroprotective effects (Allen et al., 2013).”
BackgroundMcClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Self-citationUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“Novel dual-GLP-1/GIP receptor agonists that have been developed to treat diabetes (Finan et al., 2013) or AD and PD (Hölscher, 2018) can cross the BBB at various degrees (Kastin et al.”
Background
Research works printed but not linked: 82
- Abbas, 2009, Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer’s disease., Behav. Brain Res., 205, 265, 10.1016/j.bbr.2009.06.035 · DOI · Paper page
- Athauda, 2018, Protective effects of the GLP-1 mimetic exendin-4 in Parkinson’s disease., Neuropharmacology, 136, 260, 10.1016/j.neuropharm.2017.09.023 · DOI · Paper page
- Athauda, Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the Exenatide-PD trial., JAMA Neurol., 76, 420, 10.1001/jamaneurol.2018.4304 · DOI · Paper page
- Athauda, Post hoc analysis of the Exenatide-PD trial-Factors that predict response., Eur. J. Neurosci., 49, 410, 10.1111/ejn.14096 · DOI · Paper page
- Aviles-Olmos, 2014, Motor and cognitive advantages persist 12 months after exenatide exposure in parkinson’s disease., J. Parkinson’s Dis., 4, 337, 10.3233/JPD-140364 · DOI · Paper page
- Bagetta, 2010, Synaptic dysfunction in Parkinson’s disease., Biochem. Soc. Trans., 38, 493, 10.1042/BST0380493 · DOI · Paper page
- Blurton-Jones, 2009, Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease., Proc. Natl. Acad. Sci. U. S. A., 106, 13594, 10.1073/pnas.0901402106 · DOI · Paper page
- Bove, 2012, Neurotoxin-based models of Parkinson’s disease., Neuroscience, 211, 51, 10.1016/j.neuroscience.2011.10.057 · DOI · Paper page
- Bradbury, 2005, Hope for AD with NGF gene-therapy trial., Lancet Neurol., 4, 10.1016/S1474-4422(05)70086-7 · DOI
- Cai, 2014, Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats., Neuroscience, 277, 6, 10.1016/j.neuroscience.2014.02.022 · DOI
- Cai, 2021, A GLP-1/GIP dual receptor agonist DA4-JC effectively attenuates cognitive impairment and pathology in APP/PS1/tau mice of Alzheimer’s disease., J. Alzheimer’s Dis., 83, 799, 10.3233/JAD-210256 · DOI · Paper page
- Cao, 2016, A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain., Neuroreport, 37, 384, 10.1097/WNR.0000000000000548 · DOI · Paper page
- Cao, 2018, DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer’s disease., Eur. J. Pharmacol., 827, 215, 10.1016/j.ejphar.2018.03.024 · DOI
- Clarris, 1994, Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer’s disease from hippocampal explants., J. Neurosci. Res., 38, 248, 10.1002/jnr.490380303 · DOI · Paper page
- Cork, 2015, Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain., Mol. Metab., 4, 718, 10.1016/j.molmet.2015.07.008 · DOI · Paper page
- Covaceuszach, 2009, Development of a non invasive NGF-based therapy for Alzheimer’s disease., Curr. Alz. Res., 6, 158, 10.2174/156720509787602870 · DOI · Paper page
- Doyle, 2007, Mechanisms of action of glucagon-like peptide 1 in the pancreas., Pharmacol. Ther., 113, 546, 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
- Duffy, 2013, The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease., Neuroscience, 228, 294, 10.1016/j.neuroscience.2012.10.045 · DOI
- Edison, 2020, Evaluating the Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimer’s Disease (ELAD Study).
- Faivre, D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer’s disease mouse model., J. Alzheimer’s Dis., 35, 267, 10.3233/JAD-121888 · DOI · Paper page
- Faivre, Neuroprotective effects of D-Ala2GIP on Alzheimer’s disease biomarkers in an APP/PS1 mouse model., Alz. Res. Ther., 5, 20, 10.1186/alzrt174 · DOI · Paper page
- Faivre, 2011, Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis., J. Neurophysiol., 105, 1574, 10.1152/jn.00866.2010 · DOI · Paper page
- Femminella, 2019, Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)., Trials, 20, 10.1186/s13063-019-3259-x · DOI · Paper page
- Femminella, 2020, Correction to: evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)., Trials, 21, 10.1186/s13063-020-04608-4 · DOI
- Feng, 2018, Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson’s disease., Neuropharmacology, 133, 385, 10.1016/j.neuropharm.2018.02.012 · DOI
- Foltynie, 2020, Repurposing anti-diabetic drugs for the treatment of Parkinson’s disease: rationale and clinical experience., Prog. Brain Res., 252, 493, 10.1016/bs.pbr.2019.10.008 · DOI · Paper page
- Gault, GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid., Eur. J. Pharmacol., 587, 112, 10.1016/j.ejphar.2008.03.025 · DOI
- Gault, Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid., J. Neurophysiol., 99, 1590, 10.1152/jn.01161.2007 · DOI · Paper page
- Gengler, 2012, Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice., Neurobiol. Aging, 33, 265, 10.1016/j.neurobiolaging.2010.02.014 · DOI · Paper page
- Gilman, 2003, Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons., J. Neurochem., 87, 1137, 10.1046/j.1471-4159.2003.02073.x · DOI · Paper page
- Graham, 2020, A novel mouse model of glucagon-like peptide-1 receptor expression: a look at the brain., J. Comparat. Neurol., 528, 2445, 10.1002/cne.24905 · DOI · Paper page
- Green, 2004, Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid., Arch. Biochem. Biophys., 428, 136, 10.1016/j.abb.2004.05.005 · DOI
- Han, 2013, Liraglutide protects against ß-amyloid induced impairment of spatial learning and memory in rats., Neurobiol. Aging, 32, 576, 10.1016/j.neurobiolaging.2012.04.009 · DOI
- Hedrington, 2018, Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes., Exp. Opin. Biol. Ther., 18, 343, 10.1080/14712598.2018.1439014 · DOI · Paper page
- Heese, 2006, Nerve growth factor, neural stem cells and Alzheimer’s disease., Neurosignals, 15, 1, 10.1159/000094383 · DOI · Paper page
- Hölscher, 2014, Insulin, incretins and other growth factors as potential novel treatments for Alzheimer’s and Parkinson’s diseases., Biochem. Soc. Trans., 42, 593, 10.1042/BST20140016 · DOI · Paper page
- Hölscher, 2018, Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models., Neuropharmacol, 136, 251, 10.1016/j.neuropharm.2018.01.040 · DOI · Paper page
- Hölscher, 2022, Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders., Br. J. Pharmacol., 179, 695, 10.1111/bph.15508 · DOI · Paper page
- Jalewa, 2016, Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells., J. Neurochem., 139, 55, 10.1111/jnc.13736 · DOI · Paper page
- Jalewa, 2017, A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson’s disease., Neuropharmacology, 117, 238, 10.1016/j.neuropharm.2017.02.013 · DOI
- Ji, 2016, A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson’s disease by increasing expression of BDNF., Brain Res., 1634, 1, 10.1016/j.brainres.2015.09.035 · DOI
- Kastin, 2003, Entry of exendin-4 into brain is rapid but may be limited at high doses., Int. J. Obesity Related Metabol. Disord., 27, 313, 10.1038/sj.ijo.0802206 · DOI · Paper page
- Kells, 2012, Glial-derived neurotrophic factor gene transfer for Parkinson’s disease: anterograde distribution of AAV2 vectors in the primate brain., Neurobiol. Dis., 48, 228, 10.1016/j.nbd.2011.10.004 · DOI · Paper page
- Kordower, 2013, Trophic factor gene therapy for Parkinson’s disease., Movem. Disord., 28, 96, 10.1002/mds.25344 · DOI · Paper page
- Kordower, 1997, Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates., Exp. Neurol., 145, 586, 10.1006/exnr.1997.6492 · DOI
- Langston, 1983, Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis., Science, 219, 979, 10.1126/science.6823561 · DOI · Paper page
- Leech, 1997, Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin., J. Biol. Chem., 272, 17987, 10.1074/jbc.272.29.17987 · DOI · Paper page
- Li, 2020, The novel GLP-1/GIP Analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD., Brain Behav., 10, 10.1002/brb3.1505 · DOI · Paper page
- Li, 2016, Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease., Neural. Regen. Res., 11, 326, 10.4103/1673-5374.177742 · DOI
- Li, 2016, Neuroprotective effects of a GIP analogue in the MPTP Parkinson’s disease mouse model., Neuropharmacology, 101, 255, 10.1016/j.neuropharm.2015.10.002 · DOI
- Lin, 1993, GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons., Science, 260, 1130, 10.1126/science.8493557 · DOI · Paper page
- Lv, 2021, The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-kappaB inflammatory pathway in the MPTP mouse model of Parkinson’s disease more effectively than the GLP-1 single-receptor agonist NLY01., Brain Behav., 11, 10.1002/brb3.2231 · DOI · Paper page
- Malatt, 2022, Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
- Maskery, 2020, The dual GLP-1/GIP 0gonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP/PS1 mouse model of Alzheimer’s disease, Am. J. Alzheimers Dis. Other Demen, 35, 10.1177/1533317520953041 · DOI · Paper page
- Mandel, 2010, CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer’s disease., Curr. Opin. Mol. Ther., 12, 240
- McClean, Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease., Neuropharmacology, 76, 57, 10.1016/j.neuropharm.2013.08.005 · DOI · Paper page
- McClean, 2015, Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice., Behav. Brain Res., 293, 96, 10.1016/j.bbr.2015.07.024 · DOI
- Merchenthaler, 1999, Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system., J. Comparat. Neurol., 403, 261, 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5 · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
- Migliore, 2014, Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson’s disease., Neuroscience, 274, 11, 10.1016/j.neuroscience.2014.05.019 · DOI
- Mueller, 2008, Clinical gene therapy using recombinant adeno-associated virus vectors., Gene. Ther., 15, 858, 10.1038/gt.2008.68 · DOI · Paper page
- Oka, Glucagon-like peptide-1 modulates neuronal activity in the rat’s hippocampus., Neuroreport, 10, 1643, 10.1097/00001756-199906030-00004 · DOI · Paper page
- Oka, Endogenous GLP-1 modulates hippocampal activity in beta-amyloid protein-treated rats., Neuroreport, 10, 2961, 10.1097/00001756-199909290-00016 · DOI
- Panagaki, 2018, The novel DA3-CH dual incretin restores endoplasmic reticulum stress and autophagy impairments to attenuate Alzheimer-Like pathology and cognitive decrements in the APPSWE/PS1DeltaE9 mouse model., J. Alzheimer’s Dis., 66, 195, 10.3233/JAD-180584 · DOI · Paper page
- Picconi, 2012, Synaptic dysfunction in Parkinson’s disease., Adv. Exp. Med. Biol., 970, 553, 10.1007/978-3-7091-0932-8_24 · DOI · Paper page
- Picconi, 2005, Pathological synaptic plasticity in the striatum: implications for Parkinson’s disease., Neurotoxicology, 26, 779, 10.1016/j.neuro.2005.02.002 · DOI
- Poon, 2009, beta-Amyloid impairs axonal BDNF retrograde trafficking., Neurobiol. Aging, 39, 821, 10.1016/j.neurobiolaging.2009.05.012 · DOI · Paper page
- Rafii, 2014, A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease., Alzheimer’s Dement., 10, 571, 10.1016/j.jalz.2013.09.004 · DOI · Paper page
- Schulte-Herbruggen, 2007, Neurotrophic factors–a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?, Curr. Med. Chem., 14, 2318, 10.2174/092986707781745578 · DOI · Paper page
- Shi, 2017, A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model., Behav. Brain Res., 327, 65, 10.1016/j.bbr.2017.03.032 · DOI
- Suzuki, 1997, Localization of the ATP-sensitive K+ channel subunit Kir6.2 in mouse pancreas., Diabetes, 46, 1440, 10.2337/diab.46.9.1440 · DOI · Paper page
- Talbot, 2011, The Diabetes Drug Liraglutide Ameliorates Insulin Resistance in the Hippocampal Formation of Alzheimer Disease (AD) Cases., 10.1016/j.jalz.2011.09.137 · DOI
- Usdin, 1993, Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain., Endocrinology, 133, 2861, 10.1210/endo.133.6.8243312 · DOI · Paper page
- Van Laar, 2021, An update on gene therapy approaches for Parkinson’s Disease: restoration of dopaminergic function., J. Parkinson’s Dis., 11, S173, 10.3233/JPD-212724 · DOI
- Verma, 2017, Effect of D-Ala2GIP, a stable GIP receptor agonist on MPTP-induced neuronal impairments in mice., Eur. J. Pharmacol., 804, 38, 10.1016/j.ejphar.2017.03.059 · DOI
- Wang, 2019, DA-JC1 improves learning and memory by antagonizing Abeta31-35-induced circadian rhythm disorder., Mol. Brain, 12, 10.1186/s13041-019-0432-9 · DOI
- Wang, 2013, Val(8)-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid beta peptide in rats., J. Neurosci. Res., 91, 568, 10.1002/jnr.23181 · DOI
- Wheeler, 1994, Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission., Science, 264, 107, 10.1126/science.7832825 · DOI · Paper page
- Winder, 1993, Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine., J. Neurosci., 13, 38, 10.1523/JNEUROSCI.13-01-00038.1993 · DOI · Paper page
- Yuan, 2017, A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson’s disease., Eur. J. Pharmacol., 812, 82, 10.1016/j.ejphar.2017.06.029 · DOI
- Zhang, 2020, The novel dual GLP-1/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson’s disease., J. Parkinson Dis., 10, 523, 10.3233/JPD-191768 · DOI · Paper page
- Zhang, 2015, Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model., Behav. Brain Res., 293, 107, 10.1016/j.bbr.2015.07.021 · DOI
- Zhang, 2020, GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models., Peptides, 125, 10.1016/j.peptides.2019.170184 · DOI · Paper page
Cited by
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Self-citationRhea, E. M., Babin, A., Thomas, P., Omer, M., Weaver, R., Hansen, K., Banks, W. A., & Talbot, K. (2024) · Tissue Barriers · doi:10.1080/21688370.2023.2292461 · Cited by 81
“…loss; decreased synaptic plasticity; elevated Aβ, hyperphosphorylated tau, and α-synuclein; neuroinflammation; and mitochondrial dysfunction), and cognitive deficits in animal models of AD and PD. 29,38 In the cases of albiglutide and dulaglutide, biologically active fragments (BAFs) were tested.”
Noguchi, T., Katoh, H., Nomura, S., Okada, K., & Watanabe, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1342944 · Cited by 20
Metadata
- Authors
- Hölscher, C.
- Venue
- Frontiers in Synaptic Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2022-07-27
- Volume
- 14
- Pages
- 955258-955258
- ISSN
- 1663-3563 (ISSN-L)
- OpenAlex
- W4288033440
- Cited by
- 48
- References
- 30
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases. https://app.cochat.ai/papers/10.3389/fnsyn.2022.955258
- The paper
- Hölscher, C. (2022). Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases. Frontiers in Synaptic Neuroscience. https://doi.org/10.3389/fnsyn.2022.955258
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.